A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)

The goal of this clinical trial is to determine how well people tolerate treatment with alisertib at different doses when it is used together with paclitaxel to treat people with SCLC. The main question it aims to answer is: * What percentage of side effects, both mild and serious, do participants experience when being treated with alisertib and paclitaxel based on the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE v.5.0)? The study will consist of different groups, called cohorts, in which alisertib will be studied at increasing doses. Partic

Trial Details

NCT ID
NCT07465757
Phase
PHASE2
Sponsor
Puma Biotechnology, Inc.
Status
RECRUITING
Cancer Type
Small Cell (SCLC) Lung Cancer
Interventions
  • Alisertib
  • Paclitaxel
Locations (sample)
  • Reno, Nevada, United States|39.52963,-119.8138
  • La Roche-sur-Yon, France|46.66974,-1.42757
  • Paris, France|48.85341,2.3488
  • Tomaszów Mazowiecki, Poland|51.53131,20.00855
  • Alicante, Spain|38.34517,-0.48149

Key Eligibility Criteria

  • Aged ≥18 years at signing of informed consent
  • Pathologically confirmed SCLC
  • Prior treatment with one platinum-based chemotherapy and an anti-PD-1/PD-L1 immunotherapy. Up to one additional systemic anti-cancer therapy for SC…
  • Measurable disease as defined by RECIST v1.1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Small Cell (SCLC) Lung Cancer Trials on Trialify →